Recurrent hepatitis C in liver allografts - Prospective assessment of diagnostic accuracy, identification of pitfalls, and observations about pathogenesis

被引:63
作者
Demetris, AJ
Eghtesad, B
Marcos, A
Ruppert, K
Nalesnik, MA
Randhawa, P
Wu, T
Krasinskas, A
Fontes, P
Cacciarelli, T
Shakil, AO
Murase, N
Fung, JJ
Starzl, TE
机构
[1] Univ Pittsburgh, Med Ctr, Div Transplantat, Dept Pathol, Pittsburgh, PA 15213 USA
[2] Univ Pittsburgh, Med Ctr, Div Transplantat, Dept Surg, Pittsburgh, PA 15213 USA
[3] Univ Pittsburgh, Div Hepatol, Grad Sch Publ Hlth, Pittsburgh, PA USA
[4] Univ Pittsburgh, Div Hepatol, Dept Med, Pittsburgh, PA USA
关键词
liver allograft; recurrent hepatitis; acute and chronic rejection; Banff schema; tolerance;
D O I
10.1097/00000478-200405000-00015
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Rationale and Design: The accuracy of a prospective histopathologic diagnosis of rejection and recurrent hepatitis C (HCV) was determined in 48 HCV RNA-positive liver allograft recipients enrolled in an "immunosuppression minimization protocol" between July 29, 2001 and January 24, 2003. Prospective entry of all pertinent treatment, laboratory, and histopathology results into an electronic database enabled a retrospective analysis of the accuracy of histopathologic diagnoses and the pathophysiologic relationship between recurrent HCV and rejection. Results: Time to first onset of acute rejection (AR) (mean, 107 days; median, 83 days; range, 7-329 days) overlapped with the time to first onset of recurrent HCV (mean, 115 days; median, 123 days; range, 22-315 days), making distinction between the two difficult. R and chronic rejection (CR) with and without co-existent HCV showed overlapping but significantly different liver injury test profiles. One major and two minor errors occurred (positive predictive values for AR = 91%; recurrent HCV = 100%); all involved an overdiagnosis of AR in the context of recurrent HCV. Retrospective analysis of the mistakes showed that major errors can be avoided altogether and the impact of unavoidable minor errors can be minimized by strict adherence to specific histopathologic criteria, close clinicopathologic correlation including examination of HCV RNA levels, and a conservative approach to the use of additional immunosuppression. In addition, histopathologic diagnoses of moderate and severe AR and CR were associated with relatively low HCV RNA levels, whereas relatively high HCV RNA levels were associated with a histopathologic diagnosis of hepatitis alone, particularly the cholestatic variant of HCV. Conclusions: Liver allograft biopsy interpretation can rapidly and accurately distinguish between recurrent HCV and AR/CR. In addition, the histopathologic observations suggest that the immune mechanism responsible for HCV clearance overlap with those leading to significant rejection.
引用
收藏
页码:658 / 669
页数:12
相关论文
共 42 条
[1]  
Abraczinskas D R, 2000, Transpl Infect Dis, V2, P186, DOI 10.1034/j.1399-3062.2000.020404.x
[2]   Modifications of the immune responsiveness in patients with hepatitis C virus infection following treatment with IFN-α/Ribavirin [J].
Amati, L ;
Caradonna, L ;
Magrone, T ;
Mastronardi, ML ;
Cuppone, R ;
Cozzolongo, R ;
Manghisi, OG ;
Caccavo, D ;
Amoroso, A ;
Jirillo, E .
CURRENT PHARMACEUTICAL DESIGN, 2002, 8 (11) :981-993
[3]   Impaired dendritic cell maturation in patients with chronic, but not resolved, hepatitis C virus infection [J].
Auffermann-Gratzinger, S ;
Keeffe, EB ;
Levy, S .
BLOOD, 2001, 97 (10) :3171-3176
[4]   Hepatic steatosis: A specific sign of hepatitis C reinfection after liver transplantation [J].
Baiocchi, L ;
Tisone, G ;
Palmieri, G ;
Rapicetta, M ;
Pisani, F ;
Orlando, G ;
Casciani, CU ;
Angelico, M .
LIVER TRANSPLANTATION AND SURGERY, 1998, 4 (06) :441-447
[5]   A model to predict severe HCV-related disease following liver transplantation [J].
Berenguer, M ;
Crippin, J ;
Gish, R ;
Bass, N ;
Bostrom, A ;
Netto, G ;
Alonzo, J ;
Garcia-Kennedy, R ;
Rayón, JM ;
Wright, TL .
HEPATOLOGY, 2003, 38 (01) :34-41
[6]   Natural history of recurrent hepatitis C [J].
Berenguer, M .
LIVER TRANSPLANTATION, 2002, 8 (10) :S14-S18
[7]   Analysis of the reversibility of chronic liver allograft rejection implications for a staging schema [J].
Blakolmer, K ;
Seaberg, EC ;
Batts, K ;
Ferrell, L ;
Markin, R ;
Wiesner, R ;
Detre, K ;
Demetris, A .
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 1999, 23 (11) :1328-1339
[8]   Slowly tapering off steroids protects the graft against hepatitis C recurrence after liver transplantation [J].
Brillanti, S ;
Vivarelli, M ;
De Ruvo, N ;
Aden, AA ;
Camaggi, V ;
D'Errico, A ;
Furlini, G ;
Bellusci, R ;
Roda, E ;
Cavallari, A .
LIVER TRANSPLANTATION, 2002, 8 (10) :884-888
[9]  
Chang Kyong-Mi, 2003, Clin Liver Dis, V7, P89, DOI 10.1016/S1089-3261(02)00068-5
[10]   Predictors of patient and graft survival following liver transplantation for hepatitis C [J].
Charlton, M ;
Seaberg, E ;
Wiesner, R ;
Everhart, J ;
Zetterman, R ;
Lake, J ;
Detre, K ;
Hoofnagle, J .
HEPATOLOGY, 1998, 28 (03) :823-830